Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in Major Depressive Disorder
NCT07747389Phase 3Not yet recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Nov 2026
- Primary completion
- Sep 2029
01
Overview
Phase 3, randomised, double-blind trial of lumateperone in major depressive disorder (MDD) (3 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lumateperone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07747389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747389.